Resources

Selected
  • Systematic reviews (SYSVAC)
  • Pregnant women
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date

264 results found

2025 ∙ Yasin, R. Jiang, L. Das, J. K. Bhutta, Z. A.

Interventions to Prevent and Manage Infections in Pregnancy

  • Pregnant women
  • Tetanus
  • Influenza
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Zadeh Mehrizi, T. Ataei-Pirkooh, A. Eshrati, B. Ebrahimi Shahmabadi, H.

Investigating factors affecting the effectiveness of Gardasil 4, Cervarix, and Gardasil 9 vaccines considering the WHO regions in females: A systematic review

  • Adolescents
  • Adults
  • Pregnant women
  • Human papillomavirus (HPV)
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Gavaruzzi, T. Ceccarelli, A. Nanni, C. Vignali, C. Colonnello, V. Caserotti, M. Ricco, M. Gori, D.

Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review

  • All age groups
  • Healthcare workers
  • Pregnant women
  • Parents/caregivers
  • RSV (Respiratory syncytial virus)
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Lugowski, F. Babinska, J. Urban, A. Kacperczyk-Bartnik, J. Bartnik, P. Romejko-Wolniewicz, E. Sienko, J.

Knowledge, Attitude, and Intention to Receive the Pertussis Vaccine in Pregnant Women: A Systematic Review

  • Pregnant women
  • Pertussis
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Torres-Torres, J. Rojas-Zepeda, L. Villafan-Bernal, J. R. Martinez-Portilla, R. Espino-y-Sosa, S. Cerda-Flores, P. Moreno-Verduzco, E. R. Monroy-Munoz, I. E. Gonzalez-Guerrero, A. Y. Solis-Paredes, J. M. Duran, J. P.

Maternal RSV vaccination for infant protection: A systematic review and meta-analysis of phase 3 trials with an integrated economic evaluation

  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
  • Economic aspects
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Saad, K. Alomari, O. Dizdarogullari, G. E. Mokresh, M. E. Hussein, W. M. Eyvazova, H. Kaplan, O. Ghahremanpour, G. K. Hamam, M. Api, M. Elgenidi, A. Elhoufey, A. Hassan, A. M. Temsah, M. H. Ahmad, A. R. Alnusayri, A. Abdel-Sadek, Z. M. ElAshry, A. Alhasan, K. A. Abo-Elela, M. G. M.

Maternal RSV vaccine: a systematic review and meta-analysis of immunogenicity and perinatal safety

  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Dakiniewich, A. Graham, S. Dyda, A. McHugh, L.

Pregnancy loss <28 weeks gestation in maternal influenza and COVID-19 vaccination studies: a review of data sources, 2009-2024

  • Pregnant women
  • COVID-19
  • Influenza
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Lee, B. Trusinska, D. Ferdous, S. Pei, R. Kwok, H. H. Y. Schwarze, J. Williams, T. C. Gibbons, C. Quint, J. K. Sheikh, A. Drysdale, S. B. Shi, T.

Real-world effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults: a living systematic review and meta-analysis

  • Pregnant women
  • Adults
  • Older adults
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2025 ∙ Trusinska, D. Lee, B. Ferdous, S. Kwok, H. H. Y. Gordon, B. Gao, J. Ma, L. Xiong, H. Sheikh, S. A. Schwarze, J. Busby, J. Gibbons, C. Drysdale, S. B. Ritchie, S. L. Williams, T. Shi, T.

Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis

  • Newborn
  • Children
  • Adults
  • Older adults
  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Farag, A. Elkholy, M. K. A. Genidy, A. M. Eltobgy, A.

Safety and efficacy of maternal RSV vaccination: a systematic review and meta-analysis

  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
Loading...